329 related articles for article (PubMed ID: 24225945)
1. Sclerostin inhibition reverses skeletal fragility in an Lrp5-deficient mouse model of OPPG syndrome.
Kedlaya R; Veera S; Horan DJ; Moss RE; Ayturk UM; Jacobsen CM; Bowen ME; Paszty C; Warman ML; Robling AG
Sci Transl Med; 2013 Nov; 5(211):211ra158. PubMed ID: 24225945
[TBL] [Abstract][Full Text] [Related]
2. Reversing LRP5-dependent osteoporosis and SOST deficiency-induced sclerosing bone disorders by altering WNT signaling activity.
Chang MK; Kramer I; Keller H; Gooi JH; Collett C; Jenkins D; Ettenberg SA; Cong F; Halleux C; Kneissel M
J Bone Miner Res; 2014 Jan; 29(1):29-42. PubMed ID: 23901037
[TBL] [Abstract][Full Text] [Related]
3. Co-deletion of Lrp5 and Lrp6 in the skeleton severely diminishes bone gain from sclerostin antibody administration.
Lim KE; Bullock WA; Horan DJ; Williams BO; Warman ML; Robling AG
Bone; 2021 Feb; 143():115708. PubMed ID: 33164872
[TBL] [Abstract][Full Text] [Related]
4. Sclerostin neutralization unleashes the osteoanabolic effects of Dkk1 inhibition.
Witcher PC; Miner SE; Horan DJ; Bullock WA; Lim KE; Kang KS; Adaniya AL; Ross RD; Loots GG; Robling AG
JCI Insight; 2018 Jun; 3(11):. PubMed ID: 29875318
[TBL] [Abstract][Full Text] [Related]
5. Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity.
Ellies DL; Viviano B; McCarthy J; Rey JP; Itasaki N; Saunders S; Krumlauf R
J Bone Miner Res; 2006 Nov; 21(11):1738-49. PubMed ID: 17002572
[TBL] [Abstract][Full Text] [Related]
6. Targeting the LRP5 pathway improves bone properties in a mouse model of osteogenesis imperfecta.
Jacobsen CM; Barber LA; Ayturk UM; Roberts HJ; Deal LE; Schwartz MA; Weis M; Eyre D; Zurakowski D; Robling AG; Warman ML
J Bone Miner Res; 2014 Oct; 29(10):2297-306. PubMed ID: 24677211
[TBL] [Abstract][Full Text] [Related]
7. The Anti-Osteoanabolic Function of Sclerostin Is Blunted in Mice Carrying a High Bone Mass Mutation of Lrp5.
Yorgan TA; Peters S; Jeschke A; Benisch P; Jakob F; Amling M; Schinke T
J Bone Miner Res; 2015 Jul; 30(7):1175-83. PubMed ID: 25640331
[TBL] [Abstract][Full Text] [Related]
8. Lrp4, a novel receptor for Dickkopf 1 and sclerostin, is expressed by osteoblasts and regulates bone growth and turnover in vivo.
Choi HY; Dieckmann M; Herz J; Niemeier A
PLoS One; 2009 Nov; 4(11):e7930. PubMed ID: 19936252
[TBL] [Abstract][Full Text] [Related]
9. Bone diseases: Sclerostin neutralization--a viable pathway for OPPG?
Jones B
Nat Rev Rheumatol; 2014 Jan; 10(1):4. PubMed ID: 24296680
[No Abstract] [Full Text] [Related]
10. High Bone Mass-Causing Mutant LRP5 Receptors Are Resistant to Endogenous Inhibitors In Vivo.
Niziolek PJ; MacDonald BT; Kedlaya R; Zhang M; Bellido T; He X; Warman ML; Robling AG
J Bone Miner Res; 2015 Oct; 30(10):1822-30. PubMed ID: 25808845
[TBL] [Abstract][Full Text] [Related]
11. Application of anti-Sclerostin therapy in non-osteoporosis disease models.
Jacobsen CM
Bone; 2017 Mar; 96():18-23. PubMed ID: 27780792
[TBL] [Abstract][Full Text] [Related]
12. Anti-Sclerostin antibody inhibits internalization of Sclerostin and Sclerostin-mediated antagonism of Wnt/LRP6 signaling.
van Dinther M; Zhang J; Weidauer SE; Boschert V; Muth EM; Knappik A; de Gorter DJ; van Kasteren PB; Frisch C; Mueller TD; ten Dijke P
PLoS One; 2013; 8(4):e62295. PubMed ID: 23638027
[TBL] [Abstract][Full Text] [Related]
13. LRP5: From bedside to bench to bone.
Williams BO
Bone; 2017 Sep; 102():26-30. PubMed ID: 28341377
[TBL] [Abstract][Full Text] [Related]
14. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling.
Li X; Zhang Y; Kang H; Liu W; Liu P; Zhang J; Harris SE; Wu D
J Biol Chem; 2005 May; 280(20):19883-7. PubMed ID: 15778503
[TBL] [Abstract][Full Text] [Related]
15. Sostdc1 Suppression in the Absence of Sclerostin Potentiates Anabolic Action of Cortical Bone in Mice.
Choi RB; Hoggatt AM; Horan DJ; Rogers EZ; Loots GG; Robling AG
J Bone Miner Res; 2023 May; 38(5):765-774. PubMed ID: 36891756
[TBL] [Abstract][Full Text] [Related]
16. LRP5, Bone Mass Polymorphisms and Skeletal Disorders.
Littman J; Yang W; Olansen J; Phornphutkul C; Aaron RK
Genes (Basel); 2023 Sep; 14(10):. PubMed ID: 37895195
[TBL] [Abstract][Full Text] [Related]
17. Atypical femoral fracture in osteoporosis pseudoglioma syndrome associated with two novel compound heterozygous mutations in LRP5.
Alonso N; Soares DC; V McCloskey E; Summers GD; Ralston SH; Gregson CL
J Bone Miner Res; 2015 Apr; 30(4):615-20. PubMed ID: 25384351
[TBL] [Abstract][Full Text] [Related]
18. Induction of Lrp5 HBM-causing mutations in Cathepsin-K expressing cells alters bone metabolism.
Kang KS; Hong JM; Horan DJ; Lim KE; Bullock WA; Bruzzaniti A; Hann S; Warman ML; Robling AG
Bone; 2019 Mar; 120():166-175. PubMed ID: 30409757
[TBL] [Abstract][Full Text] [Related]
19. Osteoporosis-pseudoglioma syndrome: clinical, genetic, and treatment-response study of 10 new cases in Greece.
Papadopoulos I; Bountouvi E; Attilakos A; Gole E; Dinopoulos A; Peppa M; Nikolaidou P; Papadopoulou A
Eur J Pediatr; 2019 Mar; 178(3):323-329. PubMed ID: 30499050
[TBL] [Abstract][Full Text] [Related]
20. Osteoporosis-pseudoglioma syndrome: three novel mutations in the LRP5 gene and response to bisphosphonate treatment.
Tüysüz B; Bursalı A; Alp Z; Suyugül N; Laine CM; Mäkitie O
Horm Res Paediatr; 2012; 77(2):115-20. PubMed ID: 22456437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
